Anjarium Biosciences Raises $61M in Series A Financing

Anjarium Biosciences

Anjarium Biosciences AG, a Schliren, Zurich-based biotech company focused on creating and delivering a new class of non-viral gene therapies, closed a CHF55.5M ($61M) Series A financing. 

The round was¬†co-led by Abingworth and Gimv, with participation from Omega Funds,¬†Pfizer Ventures and¬†Surveyor¬†Capital¬†(a Citadel company).¬†In conjunction with¬†Anjarium’s¬†Series A financing, Dr. Bali Muralidhar of¬†Abingworth, Dr. Bram Vanparys of¬†Gimv¬†and Dr. Dina Chaya of Omega Funds will join the company’s Board¬†of Directors.¬†

The company intends to use the funds to expand its team, advance its platform and progress several therapeutic pipeline programs towards clinical development. 

Led by Jo√ęl de Beer, Founder and CSO, Anjarium¬†Biosciences leverages a platform¬†at the interface of¬†genetic medicine,¬†synthetic biology and nanoparticle engineering to to¬†rationally¬†design and¬†produce¬†tissue-targeted gene therapies,¬†optimized to improve patient outcomes in a range of serious genetic diseases.¬†

The¬†company’s¬†platform combines proprietary DNA-based gene vectors, natural and synthetic nanoparticle delivery modalities¬†‚Ästincluding¬†its¬†novel¬†Hybridosome‚ĄĘ technology¬†‚Ästand¬†scalable¬†manufacturing¬†solutions.¬†¬†¬†¬†